Notably, studies have shown that SGLT2‐inhibitors can enhance cognitive function in elderly diabetic patients with chronic kidney disease by improving metabolism and reducing oxidative stress (Mone et al., 2024). This evidence concerns the gene SLC5A2 and chronic kidney disease.